Peng et al.37 identified entacapone, a U.S. Food and Drug Administration-approved drug that can serve as FTO inhibitors to treat metabolic disorders such as obesity and diabetes. Here, FTO is linked to obesity due to melanocortin 4 receptor deficiency.